Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A model for dissemination and independent analysis of industry data.

Literature DB >> 21990302

A model for dissemination and independent analysis of industry data.

Harlan M Krumholz¹, Joseph S Ross.

Abstract

Entities: CellLine Chemical Disease Species

Mesh：

Year: 2011 PMID： 21990302 PMCID： PMC3688082 DOI： 10.1001/jama.2011.1459

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

× No keyword cloud information.

6 in total

1. The role of litigation in defining drug risks.

Authors: Aaron S Kesselheim; Jerry Avorn
Journal: JAMA Date: 2007-01-17 Impact factor: 56.272

2. Persistence of cardiovascular risk after rofecoxib discontinuation.

Authors: Joseph S Ross; David Madigan; Marvin A Konstam; David S Egilman; Harlan M Krumholz
Journal: Arch Intern Med Date: 2010-12-13

Review 3. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Authors: Dirk Eyding; Monika Lelgemann; Ulrich Grouven; Martin Härter; Mandy Kromp; Thomas Kaiser; Michaela F Kerekes; Martin Gerken; Beate Wieseler
Journal: BMJ Date: 2010-10-12

4. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Authors: Joseph S Ross; David Madigan; Kevin P Hill; David S Egilman; Yongfei Wang; Harlan M Krumholz
Journal: Arch Intern Med Date: 2009-11-23

5. The strengths and limitations of meta-analyses based on aggregate data.

Authors: Gary H Lyman; Nicole M Kuderer
Journal: BMC Med Res Methodol Date: 2005-04-25 Impact factor: 4.615

6. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.

Authors: Joseph S Ross; Gregory K Mulvey; Elizabeth M Hines; Steven E Nissen; Harlan M Krumholz
Journal: PLoS Med Date: 2009-09-08 Impact factor: 11.069

6 in total

17 in total

A model for dissemination and independent analysis of industry data.

1. The role of litigation in defining drug risks.

2. Persistence of cardiovascular risk after rofecoxib discontinuation.

Review 3. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

4. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

5. The strengths and limitations of meta-analyses based on aggregate data.

6. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.

1. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications.

2. How do you know it is true? Integrity in research and publications: AOA critical issues.

3. Moving forward from rhBMP-2: open science and data sharing.

4. Increasing value and reducing waste: addressing inaccessible research.

5. The importance of clinical trial data sharing: toward more open science.

6. A randomized study of how physicians interpret research funding disclosures.

7. Clinical Trial Participants' Views of the Risks and Benefits of Data Sharing.

8. A historic moment for open science: the Yale University Open Data Access project and medtronic.

9. To share or not to share? Expected pros and cons of data sharing in radiological research.

10. The pulmonary hypertension academic research consortium.